Advanced therapies: post-authorisation

The European Medicines Agency's scientific and regulatory guidance on post-authorisation activities for human medicines marketed in the European Union apply to advanced therapy medicinal products (ATMPs). In addition, EMA has published specific guidance on pharmacovigilance for ATMPs.

For more information on post-authorisation activities, see Post-authorisation.

In this section


How useful was this page?

Add your rating
39 ratings
35 ratings
34 ratings
32 ratings
1 rating